Identification and evaluation of a novel glucokinase allosteric activator in target cells and animal model of type 2 diabetes

被引：0
|
作者：
Nagata, Y
Sasaki, K
Hosaka, H
Ooyama, S
Kadotani, A
Goto, H
Futamura, M
Nishimura, T
Iino, T
Bamba, M
Watanabe, H
Suzuki, J
Li, ZH
Moller, DE
Zhang, BB
Eiki, JI
机构：
来源：
DIABETES | 2004年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A139 / A139
页数：1
相关论文
共 50 条
  • [21] Identification of small-molecule glucokinase activator for type-2-diabetes treatment: a structure-based virtual screening approach
    Malini, Manokaran
    Thilagavathi, Ramasamy
    Vennila, Jannet
    Malgija, Beutline
    Praveena, Gandhi
    Selvam, Chelliah
    MOLECULAR SIMULATION, 2023, 49 (17) : 1596 - 1613
  • [22] Evaluation of the BBZDR/Wor rat: a new animal model for type 2 diabetes
    Negrin, Kimberly Anne
    Tomcho, Kayce A.
    Birckbichler, Paul J.
    FASEB JOURNAL, 2008, 22
  • [23] Evaluation of the BBZDR/Wor rat: a new animal model for type 2 diabetes
    Negrin, Kimberly A.
    Tomcho, Kayce A.
    Birckbichler, Paul J.
    FASEB JOURNAL, 2008, 22
  • [24] Pharmacological Evaluation of Jambrushila Tablet on Animal Model of Type-2 Diabetes
    Variya, Bhavesh C.
    Bakrania, Anita K.
    Shah, Prabodh V.
    Patel, Snehal S.
    NATURAL PRODUCTS JOURNAL, 2016, 6 (01): : 33 - 39
  • [25] Design and synthesis of novel glucokinase activators as potential treatments for type 2 diabetes
    McKerrecher, Darren
    Allen, Joanne V.
    Caulkett, Peter W. R.
    Donald, Craig S.
    Fenwick, Mark L.
    Grange, Emma
    Johnson, Keith M.
    Johnstone, Craig
    Jones, Cliff D.
    Pike, Kurt G.
    Rayner, John W.
    Walker, Rolf P.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 563 - 563
  • [26] Pharmacological effect of ZYGK1, a novel glucokinase activator, in hyperglycemic and sulfonylurea-resistant type 2 diabetes in mice models
    Patani, Kalpesh
    Joharapurkar, Amit
    Sundar, Rajesh
    Kshirsagar, Samadhan
    Metiya, Sunil
    Kumar, Ashutosh
    Jain, Mukul
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2025, 39 (03)
  • [27] ARRY-403, a glucokinase activator with potent glucose-dependent anti-hyperglycaemic activity in animal models of type 2 diabetes mellitus
    Hinklin, R. J.
    Aicher, T. D.
    Boyd, S. A.
    Condroski, K. R.
    DeWolf, W. E.
    Fell, J. B.
    Fischer, J.
    Lee, P. A.
    McVean, M.
    Neitzel, N. A.
    Singh, A.
    Sullivan, F. X.
    Voegtli, W.
    Wallace, E. M.
    Williams, L. M.
    DIABETOLOGIA, 2009, 52 : S342 - S342
  • [28] Effects of Piragliatin, a Glucokinase Activator, on Fasting and Postprandial Plasma Glucose in Patients With Type 2 Diabetes Mellitus
    Zhi, Jianguo
    Zhai, Suoping
    JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (02): : 231 - 238
  • [29] Characterization of a relevant animal model of type 2 diabetes for evaluating novel pharmacological interventions
    Azay-Milhau, J.
    Chapal, N.
    Dietz, S.
    Jahannault, C.
    Tournier, M.
    Cristol, J. P.
    Ribes, G.
    Petit, P.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2007, 21 : 75 - 75
  • [30] Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus
    Morrow, L. A.
    Leonsson-Zachrisson, M.
    Ericsson, H.
    Wollbratt, M.
    Knutsson, M.
    Hompesch, M.
    Norjavaara, E.
    DIABETES OBESITY & METABOLISM, 2012, 14 (12): : 1114 - 1122
12345